| 引用本文: |
郭婉薇,贾林,许鸣,杨海云,黎丽旋.六味能消胶囊联合西药治疗便秘型肠易激综合征的临床观察[J].湖南中医药大学学报,2018,38(9):1058-1061[点击复制] |
|
| |
|
|
| 本文已被：浏览 1793次 下载 574次 |
| 六味能消胶囊联合西药治疗便秘型肠易激综合征的临床观察 |
| 郭婉薇,贾林,许鸣,杨海云,黎丽旋 |
| (广州医科大学附属市一人民医院消化内科, 广东 广州 510180;广东省第二人民医院消化内科, 广东 广州 510317) |
| 摘要: |
| 目的 观察六味能消胶囊联合西药治疗便秘型肠易激综合征的临床效果。方法 选取2014年8月~2017年6月于本院消化内科就诊的120例便秘型肠易激综合征患者，按随机数字表法分为观察组与对照组，每组各60例。对照组采用枸橼酸莫沙必利分散片治疗，观察组在对照组基础上应用六味能消胶囊辅助治疗。比较两组患者治疗总有效率、治疗前后的临床症状（腹胀、腹痛、粪便性质、排便频率）评分、血管活性肠肽（vasoactive intestinal peptide，VIP）与生长抑素（somatostatin，SS）水平及治疗期间不良反应总发生率。结果 两组治疗前临床症状各指标比较差异均无统计学意义（P>0.05），治疗后两组各项评分（腹胀、腹痛、粪便性质、排便频率）较治疗前均下降（P<0.05），且观察组显著低于对照组（P<0.01）。观察组治疗总有效率为95.0%，高于对照组83.3%，差异有统计学意义（P<0.05）。治疗后两组血清VIP、SS水平较治疗前均降低（P<0.05），且观察组低于对照组（P<0.05）。观察组治疗期间不良反应总发生率与对照组比较差异无统计学意义（P>0.05）。结论 六味能消胶囊辅助治疗便秘型肠易激综合征的近期总有效率高，患者血清SS、VIP水平显著下降，临床症状缓解，安全性高，效果理想。 |
| 关键词: 六味能消胶囊 便秘型肠易激综合征 排便情况 |
| DOI：10.3969/j.issn.1674-070X.2018.09.020 |
| 投稿时间：2017-11-21 |
| 基金项目:广州市科技计划项目（20158037）。 |
|
| Clinical Efficacy of Liuwei Nengxiao Capsule Combined with Western Medicine in Treatment of Constipation-Predominant Irritable Bowel Syndrome |
| GUO Wanwei,JIA Lin,XU Ming,YANG Haiyun,LI Lixuan |
| (Department of Gastroenterology, Guangzhou First People's Hospital Affiliated to Guangzhou Medical University, Guangzhou, Guangdong 510180, China;Department of Gastroenterology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, China) |
| Abstract: |
| Objective To observe the clinical efficacy of Liuwei Nengxiao Capsule combined with Western medicine in the treatment of constipation-predominant irritable bowel syndrome (IBS-C). Methods A total of 120 patients with IBS-C who visited the Department of Gastroenterology in our hospital during August 2014 to June 2017 were enrolled and randomly divided into observation group and control group, with 60 cases in each group. The control group was treated by mosapride citrate dispersible tablets, and the observation group was treated with Liuwei Nengxiao Capsule in addition to the treatment for the control group. Comparisons were made between the two groups for overall response rate, scores of clinical symptoms (abdominal distension, abdominal pain, fecal characteristics, and frequency of defecation) before and after treatment, levels of vasoactive intestinal peptide (VIP) and somatostatin (SS), and overall incidence of adverse reactions during treatment. Results None of the clinical symptom scores showed a significant difference between the two groups before treatment (P>0.05). After treatment, all clinical symptom scores were significantly reduced in both groups (P<0.05), and were significantly lower in the observation group than in the control group (P<0.01). The overall response rate of the observation group was 95.00%, which was significantly higher than 83.3% in the control group (P<0.05). After treatment, the serum levels of VIP and SS were significantly reduced in both groups (P<0.05), and were significantly lower in the observation group than in the control group (P<0.05). The overall incidence rates of adverse reactions during treatment were not significantly different between the two groups (P>0.05). Conclusion Patients with IBS-C treated with Liuwei Nengxiao Capsule combined with Western medicine have a high overall response rate, significantly reduced serum levels of SS and VIP, and alleviated symptoms, which prove the favorable safety and efficacy of Liuwei Nengxiao Capsule. |
| Key words: Liuwei Nengxiao Capsule constipation-predominant irritable bowel syndrome defecation |
|
二维码（扫一下试试看！） |
|
|
|
|
